Wellbutrin is the brand name for bupropion, a norepinephrine-dopamine reuptake inhibitor (NDRI) FDA-approved for major depression and smoking cessation. It isn't typically used as first-line treatment for anxiety because it can be activating and worsen anxiety in some patients. It's sometimes added to an SSRI when fatigue, low motivation, or SSRI sexual side effects are limiting. It's contraindicated in patients with seizure disorders or active eating disorders.
What Wellbutrin is
Wellbutrin is the brand name for bupropion, a medication in the NDRI class. It was approved by the FDA in 1985 for major depressive disorder. Under the brand name Zyban, it's also approved for smoking cessation. Generic bupropion is widely available in immediate-release, sustained-release (SR), and extended-release (XL) forms. The MedlinePlus drug information page for bupropion covers the consumer-facing essentials.
Unlike SSRIs and SNRIs, bupropion doesn't act on the serotonin system. Its mechanism is increased dopamine and norepinephrine transmission, which gives it a distinctive profile: more activating, weight-neutral or weight-reducing, and free of the sexual side effects that limit SSRIs and SNRIs for many patients.
What it does
Bupropion blocks reuptake of norepinephrine and dopamine, increasing their availability in the synapse. The net effect is more arousal, more motivation, often more daytime energy. The antidepressant action develops over four to six weeks, similar to other antidepressants.
For anxiety specifically, this activation can cut either way. In a patient whose anxiety is driven by hypervigilance and physical arousal, more norepinephrine often makes symptoms worse, at least initially. In a patient whose depression includes prominent anxiety but also significant fatigue and amotivation, bupropion sometimes helps the energy and motivation without making the anxiety worse.
What it feels like
Patients on a working dose of Wellbutrin commonly describe more energy, easier morning starts, and improved motivation. Some describe slight jitteriness or sleep disruption in the first weeks. Appetite is often reduced.
Early side effects include insomnia (particularly when taken too late in the day), dry mouth, headache, and a transient increase in anxiety. Insomnia and anxiety symptoms usually settle over the first weeks at a stable dose; for some patients they don't, and the medication is reconsidered.
When it's chosen
Bupropion is often chosen for:
- Patients with major depressive disorder where the depression includes prominent fatigue and amotivation
- Patients on an SSRI with persistent fatigue or amotivation, where bupropion is added rather than substituted
- Patients on an SSRI with limiting sexual side effects, where bupropion is added as a partial offset
- Patients with comorbid anxiety and ADHD, where the dopaminergic effect sometimes helps both
- Smoking cessation, often combined with behavioral support
It's generally not chosen as first-line for anxiety alone. SSRIs, SNRIs, or CBT are typical first-line per the NIMH anxiety disorders overview.
Typical dosing and timeline
Starting dose of the sustained-release form is typically 150 mg once daily for one week, then 150 mg twice daily. The extended-release form starts at 150 mg daily and can be increased to 300 mg daily. The maximum dose for depression is 450 mg daily, divided to keep individual doses at 200 mg or less to reduce seizure risk.
The therapeutic effect on depression develops over four to six weeks.
Side effects and cautions
Seizure risk is the most distinctive concern. The risk is dose-related and low at standard doses in patients without other risk factors. Bupropion is contraindicated in patients with a history of seizure disorder, in patients with active eating disorders (anorexia or bulimia), and during withdrawal from alcohol or sedatives.
Activation, insomnia, dry mouth, and reduced appetite are common. Blood pressure can rise; monitoring after dose increases is reasonable in patients with hypertension. Drug interactions exist via CYP2D6 inhibition; some other psychiatric medications and some antiarrhythmics need attention.
The FDA boxed warning on increased suicidal thoughts in patients under 25 in the first months of antidepressant treatment applies. The NIMH overview of mental health medications addresses this in patient-facing language.
What Wellbutrin doesn't do
Wellbutrin isn't a first-line treatment for any anxiety disorder. For generalized anxiety, panic disorder, social anxiety, OCD, or PTSD, the evidence base for SSRIs is stronger.
Wellbutrin doesn't produce the calming effect that benzodiazepines or even SSRIs produce. Its profile is energy and motivation, not calming. Patients who expect to feel less anxious in a direct way are often disappointed and sometimes feel worse early in treatment.
Comparison with related medications
Compared with SSRIs such as Lexapro or sertraline, bupropion has no serotonin effect, no sexual side effects, and minimal weight gain, but is generally less helpful for anxiety as monotherapy. Compared with SNRIs, bupropion has a similar activating profile but acts on dopamine rather than serotonin, which makes the side effect picture quite different. In clinical practice it's more often used as an add-on to an SSRI than as monotherapy for anxiety-spectrum patients.